US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Direxion Daily S&P Biotech Bull 3x Shares

337.49

+29.169.46%

Volume:390.30K

Turnover:130.19M

Market Cap:716.99M

PE:- -

High:340.20

Open:318.40

Low:318.40

Close:308.33

52wk High:341.93

52wk Low:66.95

Shares:2.12M

Float Shares:2.12M

Volume Ratio:1.09

T/O Rate:18.37%

Dividend:1.02

Dividend Rate:0.30%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

HHS plans to add FDA deputy roles for technology, drugs, CNBC says

Zymeworks Gains $250 Million Milestone as Jazz Wins FDA Nod for HER2 Cancer Regimens

Sagimet Reiterated as Buy on De-Risked Acne Program and Clearer Regulatory Path; $29 Price Target Maintained

BeOne announces FDA approval for Tevimbra-based reginmen for HER2+ GEA

FDA approves Imaavy for warm autoimmune hemolytic anemia

U.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma

Decent Holding Provides Operational Update: Community Healthcare Network Expands to 623 Centers and Over 210,000 Paid Members

Analysts’ Top Healthcare Picks: Dyne Therapeutics (DYN), Universal Health (UHS)

Sector Update: Healthcare Stocks Edge Higher Premarket Tuesday

MT Newswires Live

Endovia launches FDA-backed CannEpil veterinary pain program

Press Release: Daré Bioscience CEO Outlines Commercial Transformation, Pipeline Momentum and Potential Key Catalysts in Virtual Investor CEO Connect Segment

Incannex Announces First Patient Dosed in DReAMzz Phase 2 Study of IHL-42X

RenovoRx Highlights Peer-Reviewed Publication of Pharmacokinetic and Pharmacodynamic (PK/PD) Data Supporting TAMP™ Platform’s Targeted Drug-Delivery in Locally Advanced Pancreatic Cancer

Endovia Health Sciences, formerly Splash Beverage, Achieves First FDA Regulatory Milestone for CannEpil® Veterinary Development Program

Teva Pharmaceutical Industries (TEVA) Could Be 10% Undervalued After FDA Accepted Ecopipam NDA

Simply Wall St.

Press Release: Vyome Holdings Reports Second Quarter 2026 Results Highlighted by Advancement of Lead VT-1953 Program, Pipeline Expansion and Strong Balance Sheet

YD Bio Announces Peer-Reviewed Publication in Nutrients, Co-Authored with Physicians from the Taiwan Chronic Disease Healthcare Association and the Future Health Institute

Incannex Begins Phase 2 DReAMzz Trial for IHL-42X

Cipla's Pithampur, India Unit Gets 7 Observations From US FDA

MT Newswires Live

Rezolute: Buy Rating Reaffirmed as FDA Catalysts Support CGM‑Driven Upside, Price Target Maintained at $6

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrdive.com/stock/LABU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"LABU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABU\",,,,,undefined,":{"symbol":"LABU","market":"US","secType":"STK","nameCN":"Direxion Daily S&P Biotech Bull 3x Shares","latestPrice":337.49,"timestamp":1787681174403,"preClose":308.33,"halted":0,"volume":390299,"delay":0,"changeRate":0.09457399539454489,"floatShares":2124486,"shares":2124486,"eps":0,"marketStatus":"Trading","change":29.16,"latestTime":"08-25 14:06:23 EDT","open":318.4,"high":340.1999,"low":318.4,"amount":130193922.57417001,"amplitude":0.070703,"askPrice":337.84,"askSize":40,"bidPrice":337.3,"bidSize":50,"shortable":3,"etf":3,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1787688000000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":308.33,"sharesOutstanding":3074486,"nav":316.946,"aum":673347221.03,"dividendRate":0.003015,"bidAskSpread":0.002803,"preHourTrading":{"tag":"盘前","latestPrice":320.4,"preClose":308.33,"latestTime":"09:29 EDT","volume":4090,"amount":1297999.7005999999,"timestamp":1787664599999,"change":12.07,"changeRate":0.039146,"amplitude":0.037817},"postHourTrading":{"tag":"盘后","latestPrice":308.6,"preClose":308.33,"latestTime":"19:56 EDT","volume":2524,"amount":779026.005,"timestamp":1787615773057,"change":0.27,"changeRate":0.000876,"amplitude":0.011327},"volumeRatio":1.089714,"impliedVol":0.9891,"impliedVolPercentile":0.7928},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABU\",,,,,undefined,":{"symbol":"LABU","floatShares":2124486,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.089714,"shares":2124486,"dividePrice":1.0175,"high":340.1999,"amplitude":0.070703,"preClose":308.33,"low":318.4,"week52Low":66.95,"pbRate":"--","week52High":341.93,"institutionHeld":0,"latestPrice":337.49,"committee":0.111111,"eps":0,"divideRate":0.003015,"volume":390299,"delay":0,"ttmEps":0,"open":318.4,"prevYearClose":159.39,"prevWeekClose":317.2,"prevMonthClose":227.4,"prevQuarterClose":292.1,"fiveDayClose":289.98,"twentyDayClose":242,"sixtyDayClose":195.3},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LABU\",params:#limit:5,,,undefined,":[{"date":"2025-09-23","symbol":"LABU","amount":0.10273,"announcedDate":"2025-09-22","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-23","defaultRemindTime":1758634200000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-30","payableDate":"2025-09-23","currency":"USD","dateTimestamp":1758600000000,"payDate":"2025-09-30"},{"date":"2025-06-24","symbol":"LABU","amount":0.21897,"announcedDate":"2025-06-23","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-24","defaultRemindTime":1750771800000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-07-01","payableDate":"2025-06-24","currency":"USD","dateTimestamp":1750737600000,"payDate":"2025-07-01"},{"date":"2025-03-25","symbol":"LABU","amount":0.10714,"announcedDate":"2025-03-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-25","defaultRemindTime":1742909400000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-01","payableDate":"2025-03-25","currency":"USD","dateTimestamp":1742875200000,"payDate":"2025-04-01"},{"date":"2024-06-25","symbol":"LABU","amount":0.15021,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-25","defaultRemindTime":1719322200000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-07-02","payableDate":"2024-06-25","currency":"USD","dateTimestamp":1719288000000,"payDate":"2024-07-02"},{"date":"2024-03-19","symbol":"LABU","amount":0.16064,"announcedDate":"2024-03-18","type":"dividend","market":"US","newRecordDate":"2024-03-20","defaultRemindTime":1710855000000,"name":"三倍做多标普生物-Direxion","recordDate":"2024-03-26","payableDate":"2024-03-20","currency":"USD","dateTimestamp":1710820800000,"payDate":"2024-03-26"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LABU\",market:\"US\",,,undefined,":[{"executeDate":"2018-06-19","recordDate":"2018-06-20","paymentDate":"2018-06-26","value":0.01932,"currency":"USD"},{"executeDate":"2018-09-25","recordDate":"2018-09-26","paymentDate":"2018-10-02","value":0.0954,"currency":"USD"},{"executeDate":"2018-12-27","recordDate":"2018-12-28","paymentDate":"2019-01-04","value":0.09621,"currency":"USD"},{"executeDate":"2019-03-19","recordDate":"2019-03-20","paymentDate":"2019-03-26","value":0.10973,"currency":"USD"},{"executeDate":"2019-06-25","recordDate":"2019-06-26","paymentDate":"2019-07-02","value":0.03745,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LABU\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LABU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2662759696","title":"HHS plans to add FDA deputy roles for technology, drugs, CNBC says","url":"https://stock-news.laohu8.com/highlight/detail?id=2662759696","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662759696?lang=en_us&edition=fundamental","pubTime":"2026-08-26 01:20","pubTimestamp":1787678453,"startTime":"0","endTime":"0","summary":"The Department of Health and Human Services is planning to create two new deputy commissioner roles at the Food and Drug Administration, one of whi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/hhs-plans-to-add-fda-deputy-roles-for-technology-drugs-cnbc-says-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/hhs-plans-to-add-fda-deputy-roles-for-technology-drugs-cnbc-says-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","BK4009","BK4588","HHS","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662756993","title":"Zymeworks Gains $250 Million Milestone as Jazz Wins FDA Nod for HER2 Cancer Regimens","url":"https://stock-news.laohu8.com/highlight/detail?id=2662756993","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662756993?lang=en_us&edition=fundamental","pubTime":"2026-08-26 00:05","pubTimestamp":1787673903,"startTime":"0","endTime":"0","summary":"The latest update is out from Zymeworks ( ($ZYME) ). Zymeworks Inc. reported that its partner Jazz Pharmaceuticals has secured U.S. Food and Drug A...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/zymeworks-gains-250-million-milestone-as-jazz-wins-fda-nod-for-her2-cancer-regimens?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/zymeworks-gains-250-million-milestone-as-jazz-wins-fda-nod-for-her2-cancer-regimens?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","LABU","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662753708","title":"Sagimet Reiterated as Buy on De-Risked Acne Program and Clearer Regulatory Path; $29 Price Target Maintained","url":"https://stock-news.laohu8.com/highlight/detail?id=2662753708","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662753708?lang=en_us&edition=fundamental","pubTime":"2026-08-25 22:45","pubTimestamp":1787669128,"startTime":"0","endTime":"0","summary":"Sagimet Biosciences, Inc. Class A, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Brandon Folkes from H.C. Wa...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/sagimet-reiterated-as-buy-on-de-risked-acne-program-and-clearer-regulatory-path-29-price-target-maintained-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/sagimet-reiterated-as-buy-on-de-risked-acne-program-and-clearer-regulatory-path-29-price-target-maintained-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBI","SGMT","BK4588","BK4585","LABU","BK4581","BK4139","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662530687","title":"BeOne announces FDA approval for Tevimbra-based reginmen for HER2+ GEA","url":"https://stock-news.laohu8.com/highlight/detail?id=2662530687","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662530687?lang=en_us&edition=fundamental","pubTime":"2026-08-25 22:45","pubTimestamp":1787669120,"startTime":"0","endTime":"0","summary":"BeOne Medicines (ONC) announced that the U.S. FDA has approved the supplemental Biologics License Application for TEVIMBRA in combination with ZIIH...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/beone-announces-fda-approval-for-tevimbra-based-reginmen-for-her2-gea-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/beone-announces-fda-approval-for-tevimbra-based-reginmen-for-her2-gea-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IYH","PINK","BK4139","BMED","IEIH","BK4588","BK4526","MEDI","TBXU","NVIB","TECB","XLVX","MRNX","IDNA","PSCH","GDOC","BK4585","GNMX","LFSC","BBP","RSPH","MRNY","ONC","IBB","LABU","SYNB","FRTY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662753010","title":"FDA approves Imaavy for warm autoimmune hemolytic anemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2662753010","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662753010?lang=en_us&edition=fundamental","pubTime":"2026-08-25 22:40","pubTimestamp":1787668811,"startTime":"0","endTime":"0","summary":"The U.S. Food and Drug Administration announced it has approved Imaavy injection for warm autoimmune hemolytic anemia in adult and pediatric patien...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/fda-approves-imaavy-for-warm-autoimmune-hemolytic-anemia-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/fda-approves-imaavy-for-warm-autoimmune-hemolytic-anemia-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4585","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662175807","title":"U.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2662175807","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662175807?lang=en_us&edition=fundamental","pubTime":"2026-08-25 22:23","pubTimestamp":1787667780,"startTime":"0","endTime":"0","summary":"Ziihera plus tislelizumab and chemotherapy approved for first-line treatment of all HER2+ GEA patients (IHC 3+ and IHC 2+/ISH+) regardless of PD-L1 status, providing a new treatment option in front-li","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/25/3350636/0/en/u-s-fda-approves-ziihera-zanidatamab-hrii-with-and-without-tislelizumab-plus-chemotherapy-in-first-line-her2-advanced-gastroesophageal-adenocarcinoma.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRC","BRRR","CBXO","GDOC","BTF","FBTC","BITU","BTCW","IBIT","CBXJ","YBTC","BITX","BCCC","CBTO","BTCL","ARKB","BTCI","DFII","NVIB","BITB","BTRN","BITI","AEIS","BTCO","BTCZ","MAXI","CBTY","IDNA","XBTY","BFAP","CBOJ","BITO","HODL","BTC","CBXY","CBTJ","DEFI","LABU","BTCC","CBTA","MNRS","CBOY","BITY","BFJL","CBOA","SBIT","GBTC","BMED","BPI","EZBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662580757","title":"Decent Holding Provides Operational Update: Community Healthcare Network Expands to 623 Centers and Over 210,000 Paid Members","url":"https://stock-news.laohu8.com/highlight/detail?id=2662580757","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662580757?lang=en_us&edition=fundamental","pubTime":"2026-08-25 21:30","pubTimestamp":1787664600,"startTime":"0","endTime":"0","summary":"YANTAI, China, Aug.  25, 2026 (GLOBE NEWSWIRE) -- Decent Holding Inc. (NASDAQ: DXST) (“Decent” or the “Company”), a technology-driven provider of wastewater treatment and community-based senior health","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/25/3350564/0/en/decent-holding-provides-operational-update-community-healthcare-network-expands-to-623-centers-and-over-210-000-paid-members.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CN","BK4550","IXJ","XLV","DXST","BK4120","XBI","BK4585","VHT","BK4588","CHCT","BK4203","BK4225","BK4581","LABU","TCAF","CGCV","KBWY","NOBL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662737038","title":"Analysts’ Top Healthcare Picks: Dyne Therapeutics (DYN), Universal Health (UHS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2662737038","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662737038?lang=en_us&edition=fundamental","pubTime":"2026-08-25 21:20","pubTimestamp":1787664011,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Dyne Therapeutics (DYN) and Universal Health (UHS) w...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-dyne-therapeutics-dyn-universal-health-uhs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-dyne-therapeutics-dyn-universal-health-uhs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4185","LU0029874061.USD","BK4505","LU0128526141.USD","BK4588","UHS","XLV","XBI","DYN","BK4585","HCSG","LABU","BK4137","BK4581","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662423737","title":"Sector Update: Healthcare Stocks Edge Higher Premarket Tuesday","url":"https://stock-news.laohu8.com/highlight/detail?id=2662423737","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662423737?lang=en_us&edition=fundamental","pubTime":"2026-08-25 21:15","pubTimestamp":1787663703,"startTime":"0","endTime":"0","summary":"Healthcare stocks were edging higher premarket Tuesday, with the State Street Health Care Select Sector SPDR ETF  slightly advancing and the iShares Biotechnology ETF  up 0.2%.Immatics  shares were up more than 13% after the company said it has agreed to sell about 12.9 million ordinary shares at $8.69 each, and in lieu of ordinary shares to certain investors, pre-funded warrants to buy up to approximately 4.3 million ordinary shares at $8.689 per pre-funded warrant.Veeva Systems  has signed Biogen  and Regeneron Pharmaceuticals  as new users for its Veeva Vault CRM platform, according to statements from Veeva. Shares of Veeva Systems were down 0.1% premarket.Bausch + Lomb  stock was up more than 1% after the company said it plans to advance two of its pharmaceutical pipeline assets to new trials based on latest clinical results.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4504","LU0234570918.USD","LABU","LU0109394709.USD","BK4588","LU0823434740.USD","BK4532","LU2362540622.SGD","BK4581","LU0882574055.USD","LU2089984988.USD","BK4139","HCSG","IBBQ","XLV","IMTX","LU2023250504.SGD","BK4613","LU0128526141.USD","LU2468319806.SGD","IE00B19Z9P08.USD","LU0320765992.SGD","REGN","BMED","EKG","LU1917777945.USD","LU0053666078.USD","VEEV","BK4533","LU2237438978.USD","BLCO","BBH","BK4528","LU0114720955.EUR","LGHT","BK4198","BK4534","LU1974910355.USD","XBI","IE00B894F039.SGD","LU0289739699.SGD","LU0058720904.USD","PBE","TBXU","IBB","LU0029874061.USD","LU0170899867.USD","LU0889565916.HKD","BIIB","LU2362541273.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662737537","title":"Endovia launches FDA-backed CannEpil veterinary pain program","url":"https://stock-news.laohu8.com/highlight/detail?id=2662737537","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662737537?lang=en_us&edition=fundamental","pubTime":"2026-08-25 20:58","pubTimestamp":1787662704,"startTime":"0","endTime":"0","summary":"Endovia Health Sciences Inc ( ($EDVA) ) just unveiled an update. On August 25, 2026, Endovia Health Sciences announced that the U.S. Food and Drug ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/endovia-launches-fda-backed-cannepil-veterinary-pain-program?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/endovia-launches-fda-backed-cannepil-veterinary-pain-program?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662732058","title":"Press Release: Daré Bioscience CEO Outlines Commercial Transformation, Pipeline Momentum and Potential Key Catalysts in Virtual Investor CEO Connect Segment","url":"https://stock-news.laohu8.com/highlight/detail?id=2662732058","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662732058?lang=en_us&edition=fundamental","pubTime":"2026-08-25 20:55","pubTimestamp":1787662500,"startTime":"0","endTime":"0","summary":"President & CEO, Sabrina Martucci Johnson, discusses the Company's shift to commercial stage, upcoming revenue opportunities, Ovaprene's positive interim Phase 3 results and what could drive value ove","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVIB","03160","BK4585","HYLG","IDNA","BK4588","GDOC","BK4555","BK4584","DARE","BK4099","BK4604","MEDX","LABU","BK4007","TM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662433737","title":"Incannex Announces First Patient Dosed in DReAMzz Phase 2 Study of IHL-42X","url":"https://stock-news.laohu8.com/highlight/detail?id=2662433737","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662433737?lang=en_us&edition=fundamental","pubTime":"2026-08-25 20:46","pubTimestamp":1787661960,"startTime":"0","endTime":"0","summary":"First patient dosing represents another major clinical milestone for IHL-42X, building on positive Phase 2 RePOSA results demonstrating reductions in AHI of up to 83% and FDA Fast Track designationNEW","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/25/3350465/0/en/incannex-announces-first-patient-dosed-in-dreamzz-phase-2-study-of-ihl-42x.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662732665","title":"RenovoRx Highlights Peer-Reviewed Publication of Pharmacokinetic and Pharmacodynamic (PK/PD) Data Supporting TAMP™ Platform’s Targeted Drug-Delivery in Locally Advanced Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2662732665","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662732665?lang=en_us&edition=fundamental","pubTime":"2026-08-25 20:30","pubTimestamp":1787661000,"startTime":"0","endTime":"0","summary":"PK/PD Data is from a Sub-Study in the Phase III TIGeR-PaC Clinical Trial The Study Shows Approximately 51% Tumor-Site Drug Extraction, Decreased Systemic Exposure, and Significant Correlation Between ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/25/3350436/0/en/renovorx-highlights-peer-reviewed-publication-of-pharmacokinetic-and-pharmacodynamic-pk-pd-data-supporting-tamp-platform-s-targeted-drug-delivery-in-locally-advanced-pancreatic-can.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B66KJ199.SGD","LABU","PK","LU2931357623.SGD","BK4023","RNXT","AEIS","BK4588","LU1815336091.USD","BK4139","BK4181","IE00B19Z4B17.USD","LU2089985449.USD","LU0274383776.USD","KBWY","LU1169589451.USD","BK4017","LU0345780281.USD","IE0031619046.USD","LU0345780521.USD","MEDX","BK4585","GDOC","IE00B7SZL793.SGD","IAG","BK4218","HYLG","PD","BK4157","NVIB","LU1169590202.USD","BK4183","IE0009354923.USD","IDNA","ODD","LU0757428866.USD","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662732575","title":"Endovia Health Sciences, formerly Splash Beverage, Achieves First FDA Regulatory Milestone for CannEpil® Veterinary Development Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2662732575","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662732575?lang=en_us&edition=fundamental","pubTime":"2026-08-25 20:30","pubTimestamp":1787661000,"startTime":"0","endTime":"0","summary":"FDA establishes Investigational New Animal Drug (INAD) File No. 14145, advancing the Company's companion-animal oncology program and marking first milestone under Lupvindol collaborationFORT LAUDERDAL","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/25/3350452/0/en/endovia-health-sciences-formerly-splash-beverage-achieves-first-fda-regulatory-milestone-for-cannepil-veterinary-development-program.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["THC","LU0130103400.USD","BK4588","LU2324357040.USD","LU1201861165.SGD","CBD","BK4585","BK4185","LU0648000940.SGD","BK4113","LABU","LU0963586101.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662581730","title":"Teva Pharmaceutical Industries (TEVA) Could Be 10% Undervalued After FDA Accepted Ecopipam NDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2662581730","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662581730?lang=en_us&edition=fundamental","pubTime":"2026-08-25 20:28","pubTimestamp":1787660886,"startTime":"0","endTime":"0","summary":"Teva Pharmaceutical Industries (NYSE:TEVA) is back in focus after the U.S. Food and Drug Administration accepted its New Drug Application for ecopipam, an investigational pediatric Tourette syndrome treatment with Orphan Drug status.\nSee our latest analysis for Teva Pharmaceutical Industries.\nThe ecopipam news lands after a strong run for Teva Pharmaceutical Industries, with a 30 day share price return of 19.86% and a 1 year total shareholder return of 103.81% that signals building momentum...","market":"us","thumbnail":"https://images.simplywall.st/asset/company-cover/308047-main-header/1585187365850","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/308047-main-header/1585187365850"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-teva/teva-pharmaceutical-industries/news/teva-pharmaceutical-industries-teva-could-be-10-undervalued","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-teva/teva-pharmaceutical-industries/news/teva-pharmaceutical-industries-teva-could-be-10-undervalued","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4588","BK4559","BK4596","LU2324357040.USD","BK4566","LU1983299246.USD","BK4584","TEVA","LABU","BK4585","BK4557","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662734825","title":"Press Release: Vyome Holdings Reports Second Quarter 2026 Results Highlighted by Advancement of Lead VT-1953 Program, Pipeline Expansion and Strong Balance Sheet","url":"https://stock-news.laohu8.com/highlight/detail?id=2662734825","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662734825?lang=en_us&edition=fundamental","pubTime":"2026-08-25 20:00","pubTimestamp":1787659200,"startTime":"0","endTime":"0","summary":"including the proposed pivotal clinical study strategy for VT-1953;received the FDA's written response on the proposed clinical development. program during the second quarter; is incorporating the FDA's feedback,preparing the appropriate supporting package, and plans to continue its","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DBB","LABU","HIND","BK4588","BK4007","BK4082","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662684732","title":"YD Bio Announces Peer-Reviewed Publication in Nutrients, Co-Authored with Physicians from the Taiwan Chronic Disease Healthcare Association and the Future Health Institute","url":"https://stock-news.laohu8.com/highlight/detail?id=2662684732","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662684732?lang=en_us&edition=fundamental","pubTime":"2026-08-25 20:00","pubTimestamp":1787659200,"startTime":"0","endTime":"0","summary":"TAIPEI, Taiwan, Aug.  25, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation–based cancer detection technology and op","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/25/3350403/0/en/yd-bio-announces-peer-reviewed-publication-in-nutrients-co-authored-with-physicians-from-the-taiwan-chronic-disease-healthcare-association-and-the-future-health-institute.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","XLV","BK4137","LU0029874061.USD","XBI","BK4585","LU0128526141.USD","LABU","HCSG","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662348617","title":"Incannex Begins Phase 2 DReAMzz Trial for IHL-42X","url":"https://stock-news.laohu8.com/highlight/detail?id=2662348617","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662348617?lang=en_us&edition=fundamental","pubTime":"2026-08-25 19:55","pubTimestamp":1787658920,"startTime":"0","endTime":"0","summary":"Incannex Healthcare Limited Sponsored ADR ( ($IXHL) ) has shared an update. On August 25, 2026, Incannex Healthcare announced that the first patien...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/incannex-begins-phase-2-dreamzz-trial-for-ihl-42x?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/incannex-begins-phase-2-dreamzz-trial-for-ihl-42x?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBI","XLV","APIE","BK4588","BK4585","CVY","BK4581","LABU","ARMH","DIVL","DINT","SAPH","AADR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662773981","title":"Cipla's Pithampur, India Unit Gets 7 Observations From US FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2662773981","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662773981?lang=en_us&edition=fundamental","pubTime":"2026-08-25 19:07","pubTimestamp":1787656033,"startTime":"0","endTime":"0","summary":"Cipla  received seven observations in Form 483 from the U.S. Food and Drug Administration after a follow-up current good manufacturing practices inspection of its manufacturing facility in Pithampur, India.The regulator inspected the Pithampur facility from Aug. 17 to Aug. 25, the pharmaceutical company said in a Tuesday filing with the Indian bourses.Cipla said it will work closely with the U.S. FDA to address the observations within the stipulated timeline.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MNDmain","BK4585","BK4588","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662736775","title":"Rezolute: Buy Rating Reaffirmed as FDA Catalysts Support CGM‑Driven Upside, Price Target Maintained at $6","url":"https://stock-news.laohu8.com/highlight/detail?id=2662736775","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662736775?lang=en_us&edition=fundamental","pubTime":"2026-08-25 18:55","pubTimestamp":1787655352,"startTime":"0","endTime":"0","summary":"In a report released today, Yun Zhong from Wedbush maintained a Buy rating on Rezolute, with a price target of $6.00. Yun Zhong has given his Buy r...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/rezolute-buy-rating-reaffirmed-as-fda-catalysts-support-cgmdriven-upside-price-target-maintained-at-6-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/rezolute-buy-rating-reaffirmed-as-fda-catalysts-support-cgmdriven-upside-price-target-maintained-at-6-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":21,"pageCount":1,"totalSize":407,"code":"91000000","status":"200"}]}}